Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment

Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative treatment in advanced melanoma, and relevant data, peer-reviewed literature, and FDA approvals in 2024. She also provides a look ahead at what is on the horizon in 2025 with regard to care for patients with advanced melanoma. In this second installment of a two-part discussion about ovarian cancer advances for The ASCO

Read the full article here

Source: ascopost.com

Categories: Oncologists1, General Medicine News

Tags: Melanoma

Tweets with this article

The ASCO Post

Don't miss this video featuring Allison Betof Warner, MD, PhD, reviewing research in the treatment of advanced #melanoma, including tumor-infiltrating lymphocyte (TIL) therapy. https://t.co/SKAoQM2tQY https://t.co/cjYwZg5bM8

LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

OncLive.com February 5, 2025

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Abstract. The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic

Blood Journal February 5, 2025

Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

OncLive.com February 5, 2025

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

CMG901 showed a manageable safety profile and had promising antitumour activity in patients with advanced gastric or gastro-oesophageal junction cancer.

The Lancet Oncology February 5, 2025

Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery

Annals of Surgical Oncology – The association of hospital market competition, financial costs, and quality of oncologic care has not been well-defined. This study sought…

AnnalsSurgOncology February 5, 2025

Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial

The assumption that thermal ablation should be reserved for unresectable colorectal liver metastases requires re-evaluation and the preferred treatment should be individualised and based on…

The Lancet Oncology February 5, 2025

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

OncLive.com February 5, 2025

Managing R/R Multiple Myeloma: Current Strategies and Future Directions in Community Practice

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR…

Targeted Oncology February 5, 2025

Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG)

Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment landscape for a wide variety of malignancies. Older adults represent a large and rapidly growing demographic,…

The Lancet Oncology February 5, 2025

FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

OncLive.com February 5, 2025

Related Articles